

GLOBAL BURDEN OF BRAIN HEALTH

Genentech

A Member of the Roche Group

Nervous system disorders impact millions of people around the world. Brain health conditions – including neurological, mental, and cerebrovascular conditions – cause more death and illness globally than cardiovascular conditions, cancers, and all other conditions.¹ Over time, the physical, mental and emotional burden can be overwhelming for patients, their families, friends and care partners, and the impact these diseases have on society at large is staggering.



600+

nervous system diseases globally²



700 MILLION

disorders that undermine how the brain develops and functions are reported globally each year³

15%

of health loss globally is associated with brain health conditions which cause more disability-adjusted life years (DALYs) than other conditions

406
million DALYs



Brain health conditions

260
million DALYs



Cancer

402
million DALYs



Cardiovascular disease

BRAIN HEALTH IN THE UNITED STATES



100 MILLION

Americans live with a neurological condition³



63.2 MILLION

years of disability-adjusted life are estimated due to brain conditions by 2050¹




\$1.2 TRILLION

estimated in total for dementia healthcare spend by 2050¹

OUR LEADERSHIP IN NEUROSCIENCE

Genentech is a biotechnology company dedicated to pursuing groundbreaking science to discover and develop medicines for people with serious and life-threatening diseases. Nowhere is the need for breakthrough medicines more profound than in brain health disorders.

As a member of the Roche Group, one of the world's largest biotechnology companies, we are uniquely positioned with our collective experience, expertise, and resources in neurological research to explore areas of the highest medical need, where there are limited or no treatment options available across our diagnostics and pharmaceuticals businesses. We know the path to scientific discovery is rarely linear and that it is marked by setbacks along with successes, but we remain undeterred.



UNWAVERING COMMITMENT IN ACTION



Roche and Genentech are the number one investors in R&D among all healthcare companies, more than \$15 billion in 2022 alone, of which more than 20% was dedicated to evaluating therapeutic, diagnostic and digital technology interventions to discover and potentially address brain health disorders.



However, this can't be done alone. Making a meaningful impact across neuroscience requires committing to a journey of discovery that involves collaborating with equally passionate advocates, coalitions and academic, institutional and industry partners.



More than 50% of our medicines have been derived from successful collaborations with hundreds of companies, universities, and institutions around the world.



More than 90% of our clinical trials in neuroscience have included patient input.



Adding to our partner efforts, we are embarking on substantial new partnerships and expanded initiatives that aim to uncover insights and make connections to continue to push the boundaries of understanding in brain health.



OUR VISION FOR THE FUTURE

Neuroscience and brain health are a cornerstone of our future. Together we will continue to push the boundaries of scientific understanding to develop breakthrough medicines, while partnering to reduce stigma, drive earlier detection and diagnosis, elevate diverse perspectives and combat inequities in the care, delivery and treatment of brain health conditions.

References:

1. Brain Health Atlas. <https://brainhealthatlas.org/>. Accessed April 12, 2023.
2. MedlinePlus. National Institutes of Health. National Library of Medicine. Neurologic Diseases. <https://medlineplus.gov/neurologicdiseases.html>. Accessed July 2019.
3. Gooch C L, Pracht E, and Borenstein AR. The burden of neurological disease in the United States: A summary report and call to action. *Ann Neurol*. 2017; 81:479-484. doi:10.1002/ana.24897.